Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab for allergic contact dermatitis
2015-004494-33Phase 2Terminated
- Sponsor
- Herlev & Gentofte Hospital
- Start
- Nov 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of secukinumab in contact hypersensitivity, sponsored by Herlev & Gentofte Hospital. Started Nov 2015; status: terminated.
02
Drugs
secukinumab
03
Conditions
contact hypersensitivity
Beyond the preview
Go deeper on 2015-004494-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004494-33.